Skip to main content

Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.

Publication ,  Journal Article
Heimberger, AB; Archer, GE; McLendon, RE; Price, D; Friedman, AH; Friedman, HS; Bigner, DD; Sampson, JH
Published in: CLINICAL CANCER RESEARCH
November 1, 2000

Duke Scholars

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

November 1, 2000

Volume

6

Start / End Page

4542S / 4543S

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heimberger, A. B., Archer, G. E., McLendon, R. E., Price, D., Friedman, A. H., Friedman, H. S., … Sampson, J. H. (2000). Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH, 6, 4542S-4543S.
Heimberger, A. B., G. E. Archer, R. E. McLendon, D. Price, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.CLINICAL CANCER RESEARCH 6 (November 1, 2000): 4542S-4543S.
Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, et al. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. 2000 Nov 1;6:4542S-4543S.
Heimberger, A. B., et al. “Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors.CLINICAL CANCER RESEARCH, vol. 6, AMER ASSOC CANCER RESEARCH, Nov. 2000, pp. 4542S-4543S.
Heimberger AB, Archer GE, McLendon RE, Price D, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa (TM)), is active against EGFR-overexpressing intracranial tumors. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2000 Nov 1;6:4542S-4543S.

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

November 1, 2000

Volume

6

Start / End Page

4542S / 4543S

Publisher

AMER ASSOC CANCER RESEARCH

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis